Answers are grounded in this paper and cite their sources.
Purpose: To investigate clock gene expression in retinoblastoma (RB) and explore the role and mechanism of nuclear receptor subfamily 1 group D member 1 (NR1D1) in RB progression. Methods: Bioinformatics analysis of the GSE58780 dataset was used to identify differentially expressed genes and clock genes in RB. The level of NR1D1 in RB tissues and cells was determined by qPCR, Western blot, and immunohistochemistry. Its role in RB was explored through gain-of-function and loss-of-function experiments. Cell growth, migration, invasion, and apoptosis were evaluated by CCK-8, EdU, Transwell, and flow cytometry. ROS levels and AKT/mTOR pathway activation were measured by flow cytometry and Western blot. A xenograft model of RB was established to explore the role of SR9009 in vivo. Results: In RB samples, clock genes CRY1, NR1D1, NR2E3, and TOX were significantly downregulated, while TIMELESS was upregulated. NR1D1 was confirmed to be significantly reduced in RB tissues. NR1D1 knockdown enhanced RB cell proliferation, migration, and invasion and inhibited apoptosis. In addition, ROS levels and the AKT/mTOR pathway was inhibited by NR1D1. In vivo, NR1D1 agonist SR9009 markedly restrained tumor growth, promoted apoptosis, and reduced AKT and mTOR phosphorylation. Conclusion: Clock genes are abnormally expressed in RB, with NR1D1 significantly downregulated. NR1D1 regulates RB growth through the ROS/AKT/mTOR pathway, and its agonist SR9009 inhibits RB tumor growth by activating NR1D1. These findings provide a potential therapeutic target for RB treatment.
No takes yet. Share an insight, caveat, or question.
Han et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: